Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) has provided an update on the regulatory pathway for its CARA artificial intelligence platform, designed for early detection of eye-related health issues. The update follows the company's previously announced acceleration plan and details progress across three targeted jurisdictions.
According to the company, it has made a formal submission to the Saudi Food and Drug Authority (SFDA) for marketing approval of CARA. Additionally, Diagnos is in ongoing engagement with Health Canada, with a formal application expected within the current quarter. In the United States, the company has clarified 510(k) requirements with the U.S. Food & Drug Administration (FDA), positioning CARA for potential commercialization in key global markets. These steps represent significant milestones in the company's strategy to bring its AI-powered diagnostic tool to healthcare providers worldwide.
The CARA platform leverages artificial intelligence to assist clinicians in detecting early signs of diabetic retinopathy and other eye-related conditions. By enhancing diagnostic accuracy and streamlining workflows, Diagnos aims to improve patient outcomes on a global scale. The company's focus on regulatory approvals in Saudi Arabia, Canada, and the United States underscores its commitment to addressing the growing burden of vision impairment and preventable blindness.
For more details on the regulatory update, the full press release is available at https://ibn.fm/uUewJ.
Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, the company aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes. Additional information about Diagnos is available at www.diagnos.com and www.sedarplus.com.
The latest news and updates relating to DGNOF are available in the company’s newsroom at https://ibn.fm/DGNOF.
